Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 3/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6095750 | 0.98 | PNMT (0.53) | PNMTALDH1A1FEN1DPP4PBRM1 | |
| SCHEMBL27701506 | 0.85 | PNMT (0.55) | PNMTALDH1A1FEN1DPP4PBRM1 | |
| SCHEMBL27853749 | 0.84 | ALDH1A1 (0.50) | ALDH1A1FEN1DPP4PBRM1TSHR | |
| SCHEMBL3006057 | 0.82 | ALDH1A1 (0.48) | ALDH1A1FEN1DPP4PBRM1TSHR | |
| SCHEMBL4504893 | 0.82 | ALDH1A1 (0.48) | ALDH1A1FEN1DPP4PBRM1TSHR | |
| SCHEMBL8477197 | 0.82 | ALDH1A1 (0.48) | ALDH1A1FEN1DPP4PBRM1TSHR | |
| SCHEMBL2866815 | 0.81 | ALDH1A1 (0.47) | ALDH1A1FEN1DPP4PBRM1TSHR | |
| SCHEMBL2336044 | 0.81 | AKR1B1 (0.62) | ALDH1A1FEN1AKR1B1FABP4 | |
| SCHEMBL1671686 | 0.81 | DPP4 (0.48) | PNMTALDH1A1FEN1DPP4TSHR | |
| Hydrochloric Acid SCHEMBL1673165 | 0.79 | DPP4 (0.47) | PNMTALDH1A1FEN1DPP4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | claimed |
| US-7053122-B2 | Therapeutic use of aryl amino acid derivatives | PFIZER INC (US) | 2006-05-30 | — | — | US | claimed |
| EP-1658059-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658058-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1528919-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2005-05-11 | — | — | EP | claimed |
| WO-2005018622-A1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018621-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043406-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | claimed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | claimed |
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2011-05-26 | — | — | US | disclosed |
| US-7053122-B2 | Therapeutic use of aryl amino acid derivatives | PFIZER INC (US) | 2006-05-30 | — | — | US | disclosed |
| US-20050043407-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | MAW GRAHAM NIGEL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004014357-A2 | THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130454-A1 | PRODRUGS OF GAMMA-AMINO ACID, ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, OPRD1 | PNMT 2499/4885ALDH1A1 1507/4885FEN1 3304/4885 |
| US-20040138197-A1 | Therapeutic use of aryl amino acid derivatives | CNR1, HCRTR1, HTR6 | PNMT 128/4885ALDH1A1 776/4885FEN1 1751/4885 |
| US-20110124705-A1 | PRODRUGS OF ALPHA-2-DELTA LIGANDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | CHRND, CHRNE, CHRNG | PNMT 3457/4885ALDH1A1 1298/4885FEN1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.